Consultant-Needed-Insert
X

Find Clinical Drug Pipeline Developments & Deals for Egrifta

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Massachusetts General Hospital

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Egrifta

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Theratechnologies

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement February 04, 2020

            Details:

            Theratechnologies Inc. signed of long-term agreements with the MGH towards the development of tesamorelin for the treatment of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis.